A benign neoplasm composed of glandular and fibrous tissues, with a relatively large proportion of glands. (Stedman, 25th ed)
Benign or borderline malignant neoplasm of the ovary and surrounding tissues. It is characterized by tumor(s) with cystic glands which are lined by cuboidal EPITHELIAL CELLS with clear cytoplasm, resembling ENDOMETRIUM cells. The glands are separated by fibroblastic STROMAL CELLS.

The expression of CCAAT/enhancer binding protein (C/EBP) in the human ovary in vivo: specific increase in C/EBPbeta during epithelial tumour progression. (1/127)

The CCAAT/enhancer binding protein (C/EBP) family of transcription factors is involved in metabolism and differentiation of cells, especially in rodent liver cells and adipocytes. Their roles in vivo and in particular during pathophysiological conditions in humans are largely unknown. We have investigated the presence of C/EBPalpha, -beta, -delta and -zeta in normal ovaries and in epithelial ovarian tumours of different stages. Immunohistochemical experiments demonstrated that C/EBPalpha and C/EBPbeta were preferentially expressed in epithelial/tumour cells irrespective of stage or grade of the tumour. C/EBPbeta was located in the nuclei of the cells, in contrast to C/EBPalpha, which was present only in the cytoplasm of these cells. The nuclear localization of C/EBPbeta indicates an active role of this transcription factor in tumour cells, whereas the cytoplasmic distribution suggests a more passive function of C/EBPalpha. C/EBPdelta and -zeta demonstrated a more diverse distribution with predominant localization to epithelial cells, but stromal distribution was also noted. The intracellular distribution was confined to both the nucleus and the cytoplasm for C/EBPdelta and -zeta. Western blotting demonstrated that C/EBPalpha, -beta, -delta and -zeta were present in a majority of the samples. The amount of C/EBPbeta increased markedly with malignancy, i.e. with degree of dedifferentiation, while the other members of the C/EBP family displayed a more constant expression level. These results demonstrate an association between the expression of members of the C/EBP family and the formation of epithelial ovarian tumours, with C/EBPbeta as a potential marker for these tumours. As C/EBPbeta is known to be expressed during proliferation of cells in vitro, it may participate in the proliferative process of ovarian epithelial tumour cells in vivo and play a central role in tumour progression.  (+info)

In vitro estrogen-binding by human breast carcinomas. (2/127)

Patients whose breast carcinomas possess only low concentrations of a receptor molecule that binds estrogens with high affinity are unlikely to respond to hormonal manipulative therapy when the disease recurs. The estrogen-binding capacity of 106 breast carcinomas was measured by an in vitro method and was expressed per milligram wet weight and in some cases related to the concentration of deoxyribonucleic acid (DNA) of the tumours. The ability of tumors to bind 3H-estradiol ranged from 0 to 1.3 fm/mg in pre- and perenopausal women, and from 0 to 16.8 fm/mg in postmenopausal women. Menopausal status or serum concentrations of endogenous estrogen, or both, should therefore be considered when tumours are classified into low and high estrogen-binding capacity. It is not necessary to carry out Scatchard analysis for every tumour, and expressing estradiol binding on the basis of DNA concentration may be preferable to expressing in on a wet-weight basis.  (+info)

Serous adenocarcinofibroma of the ovary--report of two cases and review of the literature. (3/127)

We investigated the clinical and histologic characteristics of patients with ovarian serous adenocarcinofibroma. Because the tumors in both cases contained fibroma components; they were hard and clinically indistinguishable from uterine myoma, even by computed tomography. Both patients experienced relapses associated with tumors that originated outside the abdominal cavity (the subcutaneous abdominal wall in case 1, and the inguinal lymph nodes in case 2). The serum level of CA125 was normal or only moderately elevated at the first onset and relapse. The present cases suggest that the diagnostic features and clinical course differ between ovarian serous adenocarcinoma and serous adenocarcinofibroma.  (+info)

Alterations in the expression of the DNA repair/redox enzyme APE/ref-1 in epithelial ovarian cancers. (4/127)

The DNA base excision repair pathway is responsible for the repair of alkylation and oxidative DNA damage. A crucial step in the base excision repair pathway involves the cleavage of an apurinic/apyrimidinic (AP) site in DNA by an AP endonuclease (APE). The major AP endonuclease in mammalian cells is APE/ref-1, a multifunctional enzyme that acts not only as an AP endonuclease but as a redox-modifying factor for a variety of transcription factors. The purpose of this study was to determine the expression of APE/redox factor-1 (ref-1) in ovarian tissues, particularly ovarian cancers. Formalin-fixed, paraffin-embedded specimens of ovarian tissues (normal, various benign conditions, and epithelial cancers) were studied using both polyclonal and monoclonal antibodies to APE/ref-1. The relationship between APE/ref-1 protein levels and DNA repair activity was studied in ovarian Hey and Hey-C2 cell lines using Western blot and a specific AP-site oligonucleotide cleavage assay. Hey and Hey-C2 cells were fractionated, and the nuclear and cytoplasmic extracts were quantitated for protein levels and assessed for APE/ref-1 with Western blot. Normal ovarian tissues consistently demonstrated strong nuclear staining of the surface epithelium, epithelial inclusions, corpora lutea and albicantia, and stroma. Cytoplasmic staining was absent. A similar pattern was seen for benign conditions including endometriosis. Low malignant potential ovarian cancers stained in a pattern similar to normal ovarian and nonneoplastic tissues; however, two specimens also had areas of cytoplasmic staining. Epithelial ovarian cancers were remarkably different from all other ovarian tissues studied. Both nuclear and cytoplasmic staining of the malignant epithelium were seen and ranged from strong to weak, often with considerable staining heterogeneity within the same tumor. The AP-site oligonucleotide cleavage assay indicated that APE/ref-1 protein levels correlate well with DNA repair activity. The increased levels of APE/ref-1 in the Hey-C2 cells was mainly attributable to increased cytoplasmic enzyme. APE/ref-1 immunoreactivity is altered in malignant ovarian tumors. Further studies will determine whether the altered expression and subcellular location reflect changes in redox regulatory functions.  (+info)

Accumulation of collagen in ovarian benign tumours. (5/127)

Extracellular matrix components of benign ovarian tumours (cystadenoma, adenofibroma, cystadenofibroma) were analysed. The investigated tumours contained twice as much collagen than control ovarian tissues. Significant alterations in mutual quantitative relationships between collagens of various types were observed. The proportion of type I collagen decreased and that of type III collagen increased. The accumulation of collagen was accompanied by a reduction in sulphated glycosaminoglycan content whereas the amount of hyaluronic acid was not changed. Dermatan sulphate was the most abundant glycosaminoglycan component. It is suggested that the accumulation of collagen (natural barrier to the migration of tumour cells) and underexpression of glycosaminoglycans/proteoglycans (binding some growth factors and interleukins) may exert an inhibitory effect on tumour growth.  (+info)

Contrast-enhanced sonography in the examination of benign and malignant adnexal masses. (6/127)

Our objective was to characterize the properties of an intravascular ultrasonographic contrast agent in examination of adnexal masses and to compare contrast agent properties between benign and malignant adnexal tumors. Fifty-eight consecutively examined women with suspected ovarian tumors were examined preoperatively by power Doppler ultrasonography, first without and then with contrast agent enhancement (Levovist). Fourteen women had ovarian cancer, 3 had borderline ovarian tumors, 18 had benign ovarian neoplasms, and 23 had functional adnexal cystic masses or endometriomas. The effect of the contrast agent was evaluated visually and by using computerized power Doppler signal intensity measurements. In visual evaluation, the brightness of the power Doppler signal and the amount of recognizable vascular areas increased in each tumor after contrast agent administration. The number of vessels in power Doppler ultrasonograms, both before and after contrast agent enhancement, was significantly higher in malignant than in benign adnexal masses, as also was the increase in the number of recognizable vessels after contrast agent administration. Contrast agent uptake time was significantly shorter in malignant than in benign tumors. No significant differences were found in the power Doppler signal intensities or their changes between benign and malignant tumors. In conclusion, use of sonographic contrast agent facilitates imaging of tumor vessels. For differentiation of benign and malignant tumors, the kinetic properties of the contrast agent, such as uptake and washout times, may have more potential than the use of the contrast agent in anatomic imaging of the tumor vessels.  (+info)

Apparent rat strain-related sensitivity to phorbol promotion of mammary carcinogenesis. (7/127)

It has been reported that twice-weekly i.p. injections of 4 mg phorbol for 10 weeks, after a single feeding of 6 mg dimethylbenz(a)anthracene (DMBA) in female Wistar rats, led to a significant augmentation of mammary adenocarcinoma incidence and of lymphatic leukemia incidence as compared to 6 mg DMBA alone. In an experiment reported here, in female Sprague-Dawley rats, using the same doses of DMBA and phorbol and the same injection schedule, phorbol given after DMBA did not augment mammary adenocarcinoma incidence or lymphatic leukemia incidence as compared to DMBA given alone. It thus appears that there is a strain-related sensitivity between Wistar and Sprague-Dawley rats with regard to the promoting activity of phorbol when phorbol treatment follows DMBA treatment, and mammary adenocarcinoma incidence and lymphatic leukemia incidence are studied. Further, in Sprague-Dawley rats, phorbol did not promote mammary fibroadenoma incidence in DMBA-treated rats, mammary adenocarcinoma incidence in procarbazine-treated rats, and mammary adenocarcinoma incidence or mammary fibroadenoma incidence in X-ray-treated rats. DMBA and procarbazine, with or without phorbol, tended to induce more mammary neoplasms in the anterior (thoracic) than in the posterior (abdominal) mammary glands. X-irradiation tended to induce mammary neoplasms in approximately equal numbers in the anterior and posterior mammary glands. It was suggested that regional differences in chemically induced mammary carcinogenesis were due to a difference in the transport and delivery of the chemical carcinogens to the regions rather than a difference in the amount of mammary gland tissue in the regions. An analysis of the numbers of Sprague-Dawley rats that developed either no mammary neoplasms, or only mammary adenocarcinomas, or only mammary fibroadenomas, or both mammary adenocarcinomas and mammary fibroadenomas in response to DMBA, procarbazine, and X-ray, suggested that the development of a mammary adenocarcinoma or the development of a mammary fibroadenoma are independent processes.  (+info)

Sonographic features of ovarian cystadenofibromas: spectrum of findings. (8/127)

OBJECTIVE: To describe the sonographic characteristics of ovarian cystadenofibromas. METHODS: We conducted a retrospective study of 23 ovarian tumors histopathologically confirmed as ovarian cystadenofibromas that were preoperatively evaluated by transvaginal color Doppler sonography. RESULTS: In all cases the mass was predominantly cystic. Septations appeared in 30.4% of the tumors. Papillary projections or solid nodules appeared in 56.5% of the cases. The most frequent appearance was a unilocular complex cystic mass. In 47.8% of the tumors, vascularization was detected, having a typical pattern of peripheral vascularization with scattered vessels of high blood flow impedance. CONCLUSIONS: We have described the sonographic spectrum of findings of ovarian cystadenofibromas. The most frequent appearance was a unilocular cystic mass with gross papillary projections or solid nodules. In almost half of the tumors, vascularization could be detected.  (+info)

Adenofibroma is a rare, benign tumor that occurs most commonly in the salivary glands. It is composed of both glandular tissue (adeno-) and fibrous tissue (-fibroma). These tumors are slow-growing and typically do not spread to other parts of the body.

Adenofibromas can also occur in other areas of the body, such as the skin, where they may be referred to as "fibroepithelial polyps" or "skin tags." In general, adenofibromas are not cancerous and can often be removed surgically. However, it is important to have any new growths or lumps evaluated by a healthcare professional to determine the appropriate course of treatment.

A cystadenofibroma is a rare, benign tumor that arises from the glands present in the lining of various organs, most commonly the ovary. It is composed of both cystic and fibrous tissue, with the cystic component lined by columnar epithelial cells. These tumors are usually slow-growing and do not typically spread to other parts of the body (metastasize).

Cystadenofibromas can also occur in other locations such as the respiratory tract, pancreas, and liver, but this is much less common. In general, cystadenofibromas are considered to be low-grade tumors with a good prognosis, although surgical removal is often recommended to confirm the diagnosis and prevent complications such as rupture or torsion of the tumor.

Ehdaivand S. "Ovary tumor - serous tumors - Serous cystadenoma / adenofibroma / surface papilloma". Pathology Outlines. Topic ...
Revised: 5 March 2020 Shahrzad Ehdaivand, M.D. "Ovary tumor - serous tumors - Serous cystadenoma / adenofibroma / surface ... ovarian cyst Dermoid cyst Ovarian serous cystadenoma Ovarian mucinous cystadenoma Paraovarian cyst Cystic adenofibroma ...
... adenofibroma MeSH C04.557.450.565.590.595.150 - brenner tumor MeSH C04.557.450.565.590.595.350 - fibroadenoma MeSH C04.557. ... adenofibroma MeSH C04.557.470.625.150 - brenner tumor MeSH C04.557.470.625.350 - fibroadenoma MeSH C04.557.470.660 - neoplasms ...
NOS Papillary adenofibroma M9014/0 Serous adenofibroma, NOS Serous cystadenofibroma, NOS M9014/1 Serous adenofibroma of ... Malignant serous adenofibroma Serous cystadenocarcinofibroma Malignant serous cystadenofibroma M9015/0 Mucinous adenofibroma, ... NOS M8964/3 Clear cell sarcoma of kidney M8965/0 Nephrogenic adenofibroma M8966/0 Renomedullary interstitial cell tumor ... clear cell cystadenofibroma M8313/1 Clear cell adenofibroma of borderline malignancy Clear cell cystadenofibroma of borderline ...
Adenofibroma is a biphasic neoplasm composed of benign stroma and benign epithelium. ... encoded search term (Uterus Adenofibroma/Adenosarcoma Pathology) and Uterus Adenofibroma/Adenosarcoma Pathology What to Read ... Uterus Adenofibroma/Adenosarcoma Pathology Updated: May 01, 2017 * Author: Peggy S Sullivan, MD; Chief Editor: Ramya Masand, MD ... Müllerian adenofibroma of the uterus with invasion of myometrium and pelvic veins. Int J Gynecol Pathol. 1990. 9(4):363-71. [ ...
Benign clear cell adenofibroma of the ovary. A case report with literature review. ... Benign clear cell adenofibroma of the ovary. A case report with literature review. ... Benign clear cell adenofibroma of the ovary. A case report with literature review. ... Ovarian Clear Cell Adenocarcinofibroma; ovarian clear cell adenocarcinofibroma; Ovarian Clear Cell Malignant Adenofibroma; ...
Metanephric adenofibroma. Turner Ii RM, Tomaszewski JJ, Fox JA, Galambos C, Cannon GM Jr. Turner Ii RM, et al. Among authors: ...
Ehdaivand S. "Ovary tumor - serous tumors - Serous cystadenoma / adenofibroma / surface papilloma". Pathology Outlines. Topic ...
Adenofibroma (M9013/0)*. endometrioid (M8381/0) 220. *. borderline malignancy (M8381/1) 236.2 ...
Ovarian Cancer e-Tumor Boards: Case 3: Clear Cell Carcinoma, Adenofibroma and Borderline Tumor ...
These include adenosarcoma, carcinosarcoma, Wilms tumor, adenofibroma, and adenomyoma.. Adenosarcoma. This is a biphasic tumor ...
A Clinicopathologic and Immunohistochemical Study of 55 Cases Challenging the Existence of Adenofibroma. The American Journal ...
Representative examples include serous cystadenoma, mucinous cystadenoma, clear cell adenofibroma, benign brenner tumor, ...
It could be a benign growth, which means that is non cancerous, and those include adenofibroma, fat necrosis, papilloma, or ...
Benign tumors comprise papillary adenoma, oncocytoma, metanephric adenoma, and adenofibroma Lopez- Beltran et al. ...
CLEAR CELL ADENOFIBROMA Figure 6-2 CLEAR CELL ADENOFIBROMA Small cysts in fibromatous stroma. More about this image found in ... CLEAR CELL ADENOFIBROMA Figure 6-3 CLEAR CELL ADENOFIBROMA Small tubules are lined by a single layer of clear cuboidal cells ... CLEAR CELL CARCINOMA ARISING FROM ADENOFIBROMA Figure 6-4 CLEAR CELL CARCINOMA ARISING FROM ADENOFIBROMA A: The presence of ... CLEAR CELL CARCINOMA ARISING FROM ADENOFIBROMA A: The presence of papillae... in Clear Cell Tumors > Tumors of the Ovary and ...
A knowledge graph of biological entities such as genes, gene functions, diseases, phenotypes and chemicals. Embeddings are generated with Walking RDF and OWL method ...
adenofibroma: 1. A tumor composed of connective tissue containing glandular structures. 2. A benign neoplasm composed of ...
Adenofibroma, no ICD-O subtype Active Synonym false false 2972980017 Adenofibroma, no International Classification of Diseases ... Adenofibroma, no International Classification of Diseases for Oncology subtype (morphologic abnormality). Concept Status. ... Adenofibroma, no International Classification of Diseases for Oncology subtype (morphologic abnormality). Code System Preferred ... M]Adenofibroma NOS Active Synonym false false 2770420019 ...
A knowledge graph of biological entities such as genes, gene functions, diseases, phenotypes and chemicals. Embeddings are generated with Walking RDF and OWL method ...
adenofibroma. adenosyytti. adenocyte. aborttitabletti. alternative term for aborttipilleri. adjektiiviryhmä. alternative term ...
Adenofibroma. A benign neoplasm composed of glandular and fibrous tissues, with a relatively large proportion of glands. ( ... It should be differentiated from ADENOFIBROMA which is a tumor composed of connective tissue (fibroma) containing glandular ( ... LocalOvarian NeoplasmsDisease ProgressionAdenofibromaNeoplasmsNeoplasms, Second PrimaryCell Transformation, Neoplastic ...
Young, M. D., Mitchell, T. J., Custers, L., Margaritis, T., Morales-Rodriguez, F., Kwakwa, K., Khabirova, E., Kildisiute, G., Oliver, T. R. W., de Krijger, R. R., van den Heuvel-Eibrink, M. M., Comitani, F., Piapi, A., Bugallo-Blanco, E., Thevanesan, C., Burke, C., Prigmore, E., Ambridge, K., Roberts, K., Braga, F. A. V., & 25 anderenCoorens, T. H. H., Del Valle, I., Wilbrey-Clark, A., Mamanova, L., Stewart, G. D., Gnanapragasam, V. J., Rampling, D., Sebire, N., Coleman, N., Hook, L., Warren, A., Haniffa, M., Kool, M., Pfister, S. M., Achermann, J. C., He, X., Barker, R. A., Shlien, A., Bayraktar, O. A., Teichmann, S. A., Holstege, F. C., Meyer, K. B., Drost, J., Straathof, K. & Behjati, S., 23 jun. 2021, In: Nature communications. 12, 1, blz. 3896 3896.. Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review ...
Metanephric adenoma is part of a family of neoplasms that includes the even rarer metanephric adenofibroma (54) and metanephric ...
Photo Options that come with Carcinosarcoma Arising from Adenofibroma from the Uterus: An incident. * Post author By admin ... No Comments on Photo Options that come with Carcinosarcoma Arising from Adenofibroma from the Uterus: An incident ...
Leave a comment on Image resolution Top features of Carcinosarcoma Arising from Adenofibroma in the Womb: An incident ... Image resolution Top features of Carcinosarcoma Arising from Adenofibroma in the Womb: An incident. Checks through with 1,3- ... Image resolution Top features of Carcinosarcoma Arising from Adenofibroma in the Womb: An incident ...
Uterine adenofibroma is an extremely rare benign mixed mullerian tumor, most often presenting as vaginal mass with pain and ... We present a rare case of nonpuerperal uterine inversion due to a uterine adenofibroma. A 56-year-old postmenopausal female ... Uterine Adenofibroma: An Unsual Cause of Nonpuerperal Uterine Inversion in Postmenopausal Female. ... Histopathological evaluation showed uterine adenofibroma. This is the first case of inversion reported due to uterine ...
Borderline Clear Cell Adenofibroma of the Ovary.. Kleebkaow, P. Aue-Aungkul, A. Temtanakitpaisan, A. Kietpeerakool, C. 2017. ... Borderline Clear Cell Adenofibroma of the Ovary. Kleebkaow, P. Aue-Aungkul, A. Temtanakitpaisan, A. Kietpeerakool, C. 2017. ... Borderline Clear Cell Adenofibroma of the Ovary. Pilaiwan Kleebkaow. Apiwat Aue-aungkul. Amornrat Temtanakitpaisan. Chumnan ...
Borderline Clear Cell Adenofibroma of the Ovary.. Kleebkaow, P. Aue-Aungkul, A. Temtanakitpaisan, A. Kietpeerakool, C. 2017. ... Borderline Clear Cell Adenofibroma of the Ovary.. Pilaiwan Kleebkaow. Apiwat Aue-aungkul. Amornrat Temtanakitpaisan. Chumnan ... Borderline Clear Cell Adenofibroma of the Ovary. Pilaiwan Kleebkaow. Apiwat Aue-aungkul. Amornrat Temtanakitpaisan. Chumnan ...
boran alterableness adenofibroma April 7, 2013 1:14 am this for about a month and one… ...
Adenofibroma: Can be diagnosed in curettings or biopsy materials. Art Color Ballet is a modern dance company, established in ...
An adenofibroma is a benign tumor of the breast tissue.. *Fibrocystic breasts are breasts that are painful and lumpy due to ...
  • Benign clear cell adenofibroma of the ovary. (nih.gov)
  • [ 1 ] whereas adenofibroma is a biphasic neoplasm composed of benign stroma and benign epithelium. (medscape.com)
  • Benign tumors comprise papillary adenoma, oncocytoma, metanephric adenoma, and adenofibroma Lopez- Beltran et al. (malaimare.ro)
  • An adenofibroma is a benign tumor of the breast tissue. (ultracarediagnosticimaging.com)
  • Occasional cases of adenofibroma have been associated with tamoxifen therapy. (medscape.com)
  • Intraglandular polypoid projections characterize adenofibroma/adenosarcoma at low power (hematoxylin and eosin stain, x200). (medscape.com)
  • Adenofibroma is an uncommon neoplasm, comprising 5% of a large series of adenosarcomas/adenofibromas. (medscape.com)
  • Adenofibroma is an uncommon neoplasm, comprising 5% of a large series of adenosarcomas/adenofibromas. (medscape.com)
  • 2. Metanephric adenofibroma. (nih.gov)